ERASCA, INC. ERAS 深 滬
等待開盤 08-14 09:30:00 美东时间
1.615
+0.055
+3.53%
華盛通- 最 高1.705
- 今 開1.55
- 成交量 79.02万股
- 最 低 1.531
- 昨 收 1.56
- 總市值 4.57亿
- 52周最高 3.305
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 1.01
- 委 比 35.16%
- 總股本 2.83亿
- 歷史最高 24.47
- 量 比 1.80
- 振 幅 11.15%
- 歷史最低 1.01
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Erasca Q2 EPS $(0.12) Misses $(0.11) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 58.62 percent increase over losses of $(0.29) per share from the same
08-13 04:16
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
Erasca, Inc. announced updates on its RAS-targeting therapies, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), with Phase 1 monotherapy data expected in 2026. The company highlighted IND clearances for both candidates and robust financials, including $387 million in cash as of June 2025, supporting operations into H2 2028. Q2 2025 R&D expenses were $21.2 million, down from $33.0 million in Q2 2024, while G&A expenses fell t...
08-12 20:01
杜莎夫人蜡像馆揭幕史上最大规模的蜡像发布项目
杜莎夫人蜡像馆揭幕史上最大规模的蜡像发布项目，推出13尊全新泰勒·斯威夫特（Taylor Swift）蜡像，将于四大洲13个城市同步登场。这次多尊蜡像同步发布是...
07-24 10:39
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulle...
06-30 23:02
Erasca Confirms Directors and Ratifies KPMG Appointment
Erasca ( ($ERAS) ) has issued an announcement. On June 24, 2025, Erasca, Inc. h...
06-27 05:30
Erasca Secures FDA Clearance For First-In-Class Pan-KRAS Inhibitor ERAS-4001
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidanceInitial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026SAN
06-02 20:29
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
Erasca Inc. announced FDA clearance for its IND application for ERAS-4001, a potential first-in-class pan-KRAS inhibitor, for treating KRAS-mutant solid tumors. Both ERAS-4001 and ERAS-0015, a potential best-in-class pan-RAS molecular glue, received IND clearance ahead of company guidance. Initial Phase 1 monotherapy data for both RAS-targeting programs are expected in 2026. ERAS-4001 targets multiple KRAS mutations and wildtype KRAS while sparin...
06-02 12:00
Erasca to Present at Upcoming Investor Conferences in June
Erasca, Inc. announced that its management will participate in two investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4 and the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach on June 10. Both events will feature fireside chats, with live audio webcasts available online via Erasca.com/events. An archived replay will be accessible for 30 days post-event. Erasca, a precision oncol...
05-29 12:00
Erasca shares are trading higher after the company reported better-than-expected Q1 EPS results.
Erasca shares are trading higher after the company reported better-than-expecte...
05-14 22:21
